Literature DB >> 133299

Cerebrospinal fluid gamma-aminobutyric acid in neurologic disease.

V S Achar, K M Welch, E Chabi, K Bartosh, J S Meyer.   

Abstract

Cerebrospinal fluid gamma-aminobutyric acid (CSF GABA) was analyzed in 151 patients who underwent evaluation for central nervous system disease. CSF GABA was not detected in 19 of these patients, who had no evidence of neurologic disease and who served as controls. GABA was most frequently detected in patients with cerebrovascular disease, and was detected only in Parkinson's syndrome of atherosclerotic origin and dementia of multi-infarct type. CSF GABA was not detected in Alzheimer's disease or Huntington's disease. Patients with grand mal seizures exhibited CSF GABA elevation within 24 hours of the ictus. In patients with multiple sclerosis GABA detection was related to the presence or exacerbation of spinal cord lesions. Further study is necessary to evaluate the significance of elevated CSF GABA in central nervous system disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 133299     DOI: 10.1212/wnl.26.8.777

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

Review 1.  Clinical relevance of measuring GABA concentrations in cerebrospinal fluid.

Authors:  P J Schechter; A Sjoerdsma
Journal:  Neurochem Res       Date:  1990-04       Impact factor: 3.996

Review 2.  The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.

Authors:  Rachel R Robinson; Alina K Dietz; Asif M Maroof; Reto Asmis; Thomas G Forsthuber
Journal:  Immunotherapy       Date:  2019-02       Impact factor: 4.196

3.  Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome.

Authors:  R Crols; J Saerens; M Noppe; A Lowenthal
Journal:  J Neurol       Date:  1986-06       Impact factor: 4.849

4.  Effects of GABA, glycine, and sodium barbiturate on dendritic growth in vitro.

Authors:  S J Baloyannis; K Karakatsanis; J Karathanasis; M Apostolakis; A Diacoyannis
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

Review 5.  Alterations of central GABAergic activity in neurologic and psychiatric disorders: evaluation through measurements of GABA and GAD activity in cerebrospinal fluid.

Authors:  T A Hare
Journal:  Mol Cell Biochem       Date:  1981-09-25       Impact factor: 3.396

6.  Plasma and cerebrospinal fluid gamma-aminobutyric acid in neurological disorders.

Authors:  D Schmidt; W Löscher
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-10       Impact factor: 10.154

7.  The response to isoniazid of action tremor in multiple sclerosis and its assessment using polarised light goniometry.

Authors:  D A Francis; D Grundy; J R Heron
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-01       Impact factor: 10.154

Review 8.  gamma-Aminobutyric acid and cardiovascular function.

Authors:  F V DeFeudis
Journal:  Experientia       Date:  1983-08-15

Review 9.  Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis.

Authors:  Georgia Mandolesi; Antonietta Gentile; Alessandra Musella; Diego Fresegna; Francesca De Vito; Silvia Bullitta; Helena Sepman; Girolama A Marfia; Diego Centonze
Journal:  Nat Rev Neurol       Date:  2015-11-20       Impact factor: 42.937

Review 10.  A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.

Authors:  Edina Silajdžić; Maria Björkqvist
Journal:  J Huntingtons Dis       Date:  2018
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.